Due to the emergence of vancomycin resistance, E. faecium has become the main cause of multi-drug resistant enterococal infection. In recent years, the proportion of vancomycin resistance in enterococcal infection is increasing, which has great potential for outbreaks due to medical reasons, but its treatment options are limited. On the basis of an in-depth understanding of drug-resistant bacteria, Creative Biolabs provides one-stop services for antibacterial drug discovery and development against severe bacterial pathogens, such as E. faecium
E. faecium is a Gram-positive lactic acid bacterium that belongs to hemolytic or non-hemolytic Enterococcus. Generally speaking, it is a facultative anaerobic organism, which can survive at 60 ℃ for a short time and grow at high salt concentration. It is generally found in the normal intestinal flora of humans and animals. Enterococcus species have long been considered as important human pathogens and are becoming more and more important. One of the main benefits of E. faecium is that it is particularly suitable for survival during digestion and reproduction in the gut. It promotes the balance of the intestinal environment by competing for resources consumed and utilized by pests. It also competes with harmful organisms for adhesion sites - areas on the cell surface where other cells and molecules can bind. Therefore, this "multitasking" strain is commonly found in human probiotic supplements.
For many years, E. faecium has been regarded as a symbiotic bacterium of the digestive tract, which only occasionally causes opportunistic infection in severely ill patients. However, there is more and more evidence that some strains of E. faecium may be pathogenic, harmful to humans, and may cause bacteremia, endocarditis, urinary tract infection, and other infections.
At present, antimicrobial resistance (AMR) to many commonly used antibiotics has been reported, and E. faecium is the main cause of human multi-drug resistant (MDR) enterococci infection. Among them, vancomycin-resistant E. faecium (VREF) has become an important cause of nosocomial infection worldwide, which has a negative impact on the survival rate of patients with E. faecium bacteremia and leads to higher medical costs. In addition, acquired resistance of E. faecium to glycopeptide is also common. Infections caused by anti-glycopeptide Enterococci are difficult to treat because there are only a few treatment options available. Therefore, the safety of E. faecium as a probiotic food additive is concerned.
The characteristics of E. faecium have attracted people's attention to the safety of probiotics containing these bacteria, and the development of antibacterial drugs against it is imminent. As one of the world's leading contract research companies, Creative Biolabs provides comprehensive solutions to help you efficiently discover antibacterial drugs.
Our one-stop service participates in every step of your drug development, at the same time, we can customize the design of the research to meet all your special research needs.
If you are interested in our service, please feel free to contact us.
For Research Use Only.
